ALNY Alnylam Pharmaceuticals Earnings and EPS analysis

Relative Growth: Rel. Growth: 95

Relative Strength: Rel. Strength: 7

Relative Valuation: Rel. Valuation: 59

Relative Profitability: Rel. Profitability: 98

EPS in 2026 (TTM): $6.1

Last Report Period Date: Jun 30, 2026

According to the most recent financial data from June 2026, the EPS for the trailing twelve months is $6.1. Alnylam Pharmaceuticals's EPS for 2025 amounted to $2.39, marking an increase from -$2.18 in 2024. During the quarterly period ending on Jun 30, 2026, ALNY's EPS stood at $1.23.

ALNY earnings history

Historical annual and quarterly earnings per share (EPS) data for Alnylam Pharmaceuticals

EPS (TTM)

$6.1

EPS Growth YoY (Quarterly)

323.6%

EPS (Quarterly)

$1.23

EPS Growth (Quarterly)

-20.6%

Alnylam Pharmaceuticals had an annual EPS of $2.39, indicating an increase of 209.6% from -$2.18 in 2024. The quarterly per-share earnings for the period ending Jun 30, 2026, was $1.23, indicating a 323.6% increase from the same quarter last year. ALNY's 12-month EPS stands at $6.1 as of June 2026. Alnylam Pharmaceuticals's annual EPS in 2024 stood at -$2.18, a 38.1% increase year-over-year.

ALNY earnings chart

ALNY EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

323.6%

EPS growth YoY

209.6%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

During the last 12 months, Alnylam Pharmaceuticals has seen an EPS growth of 323.6% (YoY, quarterly).

ALNY Earnings Waterfall

Breakdown of revenue, profit and net income for Alnylam Pharmaceuticals

ALNY Earnings vs Peers

What are the earnings of ALNY compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
REGN Regeneron Pharmaceuticals Inc	18.28	5.3%	2.1%	5.7%
NVS Novartis AG	23.34	21.8%	31.2%	15.2%
SRPT Sarepta Therapeutics Inc	24.83	-388.7%	N/A	N/A
ALNY Alnylam Pharmaceuticals Inc	34.98	209.6%	N/A	N/A
TEVA Teva- Pharmaceutical Industries Ltd	55.19	184.8%	N/A	N/A
ARWR Arrowhead Pharmaceuticals Inc	N/A	99.8%	N/A	N/A
OPK Opko Health Inc	N/A	-275%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.